Screening for Chemotherapy-induced Peripheral Neuropathy and Utilization of Physical Therapy in Pediatric Patients Receiving Treatment for Hematologic Malignancies

J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e358-e361. doi: 10.1097/MPH.0000000000002202.

Abstract

Physical therapy (PT) has been shown to be a helpful intervention in the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Our aim was to screen for CIPN in patients with hematologic malignancies receiving vincristine chemotherapy and obtain a baseline assessment on the percentage of patients utilizing PT in the treatment of CIPN. A retrospective review of surveys administered to parents and patients regarding the severity of peripheral neuropathy symptoms from October 2016 through March 2018 was conducted. Of 116 patients, a total of 102 patients (67 male and 35 female; 4 to 10 y of age, N=63; 11 to 15 y of age, N=19; 16 to 20 y of age, N=20) were eligible for the study, with 67.6% (N=69) reporting symptoms of CIPN. Of these patients, 16.7% scored 4 or greater on the surveys, suggesting clinically severe CIPN. Common parental concerns included decreased strength, difficulty walking up stairs, tripping, and foot drops. Approximately 55.1% of the 69 patients who reported CIPN symptoms were referred to outpatient PT, while 44.9% were not referred. A simple survey consisting of 4 questions that only took several minutes to administer was capable of identifying CIPN in 67.6% of patients receiving vincristine chemotherapy.

MeSH terms

  • Adult
  • Antineoplastic Agents* / adverse effects
  • Child
  • Female
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases* / chemically induced
  • Peripheral Nervous System Diseases* / diagnosis
  • Physical Therapy Modalities
  • Quality of Life
  • Vincristine / adverse effects
  • Young Adult

Substances

  • Antineoplastic Agents
  • Vincristine